Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 2
1979 4
1980 29
1981 23
1982 27
1983 46
1984 35
1985 41
1986 43
1987 50
1988 35
1989 56
1990 32
1991 43
1992 34
1993 32
1994 32
1995 22
1996 27
1997 19
1998 14
1999 18
2000 19
2001 19
2002 20
2003 8
2004 12
2005 18
2006 19
2007 15
2008 14
2009 13
2010 9
2011 7
2012 10
2013 16
2014 9
2015 24
2016 21
2017 11
2018 12
2019 17
2020 20
2021 15
2022 16
2023 18
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

1,010 results

Results by year

Filters applied: . Clear all
Page 1
Aclarubicin stimulates RNA polymerase II elongation at closely spaced divergent promoters.
Wooten M, Takushi B, Ahmad K, Henikoff S. Wooten M, et al. Sci Adv. 2023 Jun 16;9(24):eadg3257. doi: 10.1126/sciadv.adg3257. Epub 2023 Jun 14. Sci Adv. 2023. PMID: 37315134 Free PMC article.
We also found that aclarubicin treatment changes the distribution of noncanonical DNA G-quadruplex structures both at promoters and at G-rich pericentromeric repeats. Our work suggests that the cancer-killing activity of aclarubicin is driven by the disruption of nu …
We also found that aclarubicin treatment changes the distribution of noncanonical DNA G-quadruplex structures both at promoters and a …
The identification of the anthracycline aclarubicin as an effective cytotoxic agent for pancreatic cancer.
Brouwer TP, van der Zanden SY, van der Ploeg M, van Eendenburg JDH, Bonsing BA, de Miranda NFCC, Neefjes JJ, Vahrmeijer AL. Brouwer TP, et al. Anticancer Drugs. 2022 Aug 1;33(7):614-621. doi: 10.1097/CAD.0000000000001283. Epub 2022 Mar 23. Anticancer Drugs. 2022. PMID: 35324522 Free PMC article.
In parallel, evaluation of the antitumor activity of aclarubicin demonstrated an apoptotic effect in all PDAC cell lines. ...Our findings support a (re)consideration of aclarubicin as a backbone of new combination regimens for pancreatic cancer patients....
In parallel, evaluation of the antitumor activity of aclarubicin demonstrated an apoptotic effect in all PDAC cell lines. ...Our find …
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.
Wander DPA, van der Zanden SY, van der Marel GA, Overkleeft HS, Neefjes J, Codée JDC. Wander DPA, et al. J Med Chem. 2020 Nov 12;63(21):12814-12829. doi: 10.1021/acs.jmedchem.0c01191. Epub 2020 Oct 16. J Med Chem. 2020. PMID: 33064004 Free PMC article.
Anthracycline anticancer drugs doxorubicin and aclarubicin have been used in the clinic for several decades to treat various cancers. ...For a better understanding of the structure-function relationship of these drugs, we synthesized ten doxorubicin/aclarubicin hybr …
Anthracycline anticancer drugs doxorubicin and aclarubicin have been used in the clinic for several decades to treat various cancers. …
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. Wei G, et al. J Hematol Oncol. 2011 Nov 14;4:46. doi: 10.1186/1756-8722-4-46. J Hematol Oncol. 2011. PMID: 22082134 Free PMC article. Review.
The regimen of cytarabine, aclarubicin and G-CSF (CAG) has been widely used in China and Japan for treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ...
The regimen of cytarabine, aclarubicin and G-CSF (CAG) has been widely used in China and Japan for treatment of acute myeloid leukemi …
Aclarubicin in subtoxic doses reduces doxorubicin cytotoxicity in human non-small cell lung adenocarcinoma (A549) and human hepatocellular carcinoma (HepG2) cells by decreasing DNA damage.
Gajek A, Rogalska A, Koceva-Chyła A. Gajek A, et al. Toxicol In Vitro. 2019 Mar;55:140-150. doi: 10.1016/j.tiv.2018.12.015. Epub 2018 Dec 20. Toxicol In Vitro. 2019. PMID: 30579959
In the study, the cytotoxicity and genotoxicity of aclarubicin (ACL) against A549 (human non-small cell lung adenocarcinoma) and HepG2 (human hepatocellular carcinoma) cell lines were evaluated and compared with that of doxorubicin (DOX). ...
In the study, the cytotoxicity and genotoxicity of aclarubicin (ACL) against A549 (human non-small cell lung adenocarcinoma) and HepG …
Rethinking Biosynthesis of Aclacinomycin A.
Xu Z, Tian P. Xu Z, et al. Molecules. 2023 Mar 18;28(6):2761. doi: 10.3390/molecules28062761. Molecules. 2023. PMID: 36985733 Free PMC article. Review.
Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.
Kong FC, Qi L, Zhou YL, Yu M, Huang WF, Li F. Kong FC, et al. Curr Med Sci. 2023 Dec;43(6):1151-1161. doi: 10.1007/s11596-023-2805-7. Epub 2023 Dec 7. Curr Med Sci. 2023. PMID: 38057538
METHODS: Clinical data of R/R AML patients who received a CDCAG regimen (chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor) from July 1, 2018 to October 31, 2021 at our center were retrospectively assessed, and the safety and efficac …
METHODS: Clinical data of R/R AML patients who received a CDCAG regimen (chidamide, decitabine, cytarabine, aclarubicin, and granuloc …
1,010 results